| Monday February 27 |
| 9:00am |
Welcome & Introduction
Cheryl Arrowsmith, SGC and Ontario Cancer Institute |
|
| |
Session 1 - Genomic and Epigenomic Signatures in Cancer and Stem Cells
Chair – Michael Taylor - Hospital for Sick Children |
| 9:05am |
Ultan McDermott - Wellcome Trust Sanger Institute
Integrating complex genomic datasets and high-throughput cancer cell lines |
| 9:40am |
Brad Bernstein - Harvard Medical School and Broad Institute
Reconstructing Cellular Networks from Chromatin States |
| 10:15am |
Joseph Costello - University of California, San Francisco
Mutations and epimutations that drive malignant transformation |
|
| 10:50am |
Coffee Break |
|
| |
Session 2 - Molecular Mechanisms of Epigenetic Regulation in Cancer
Chair – Aled Edwards - SGC & University of Toronto |
| 11:20am |
Shiv Grewal - NIH National Cancer Institute
Heterochromatin assembly and epigenetic genome control by non-coding and coding RNAs |
| 11:55am |
Rod Bremner - Toronto Western Research Institute
BRG1 versus Polycomb - a new battle site |
| 12:30pm |
Charles Brenner - University of Iowa
Novel Macromolecular and Small Molecule Inhibitors of DNMT1 |
|
| 1:05pm |
Lunch Break |
|
| |
Session 3 - Epigenetic Mechanisms in Cancer
Chair - Linda Penn - Ontario Cancer Institute |
| 2:20pm |
Peter Scacheri - Case Western Reserve University
Enhancer-mediated Gene Dysregulation in Cancer |
| 2:55pm |
Mathieu Lupien - Dartmouth University & Ontario Cancer Institute
Remodeling of the Chromatin Landscape Underlies Endocrine Response in Breast Cancer |
| 3:30pm |
Peggy Farnham - University of Southern California
Regulation of the Cancer Epigenome by the KAP1-SETDB1 complex |
| 4:05pm |
Shohei Koide - University of Chicago
Renewable, recombinant antibodies to histone marks |
|
| 4:30pm |
Poster Session/Reception |
| Tuesday February 28 |
| |
Session 4 - Toward Therapeutic Targeting of Epigenetic Regulatory Factors
Chair – Mark Minden - Ontario Cancer Institute |
| 9:00am |
Stephen D Nimer - Memorial Sloan Kettering Cancer Center
Leukemogenic Properties of Histone Modifying Enzymes |
| 9:35am |
Ari Melnick - Weill Cornell Medical School
Epigenetic basis and therapeutic targeting of hematologic malignancies |
| 10:10am |
Fabio Rossi - University of British Columbia
The role of H3K9me2 methyltransferase G9a in myeloid leukemia |
|
| 10:45am |
Coffee Break |
|
| |
Session 5 - Targeting Epigenetic Misregulation in Hematologic Malignancies
Chair – Peter Dirks - Hospital for Sick Children |
| 11:20am |
Stefan Knapp - University of Oxford
Bromo Domains: a family of druggable epigenetic effector domains |
| 11:55am |
James Bradner - Dana Farber Cancer Institute
Targeting Bromo Domains in Cancer |
| 12:30pm |
Dash Dhanak - GlaxoSmithKline
EZH2, Inhibitors and Cancer |
|
| 1:05pm |
Lunch Break |
|
| 2:15pm |
Keynote: Stephen Baylin - Johns Hopkins University
Where are we in understanding the origins of the cancer epigenome and
realizing the translational potential of the concept?
Chair – Cheryl Arrowsmith - SGC & Ontario Cancer Institute |
|
| 2:55pm |
Round Table on Epigenetics & Personalized Medicine in Cancer
Moderators:
- Cheryl Arrowsmith - SGC & Ontario Cancer Institute
- Mark Minden - Ontario Cancer Institute
Panel: Stephen Baylin, Peter Dirks, James Bradner, Mathieu Lupien, Joseph Costello, Ultan McDermott, Linda Penn |
